|
| General Information |
| Business: |
We are a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that we apply to the discovery and development of protein therapeutics to treat diseases of the eye. Our therapeutic approach is based on the role of cytokines in diseases of the eye, our understanding of the structural biology of cytokines and our ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects. Our most advanced product candidate is EBI-005, which we designed, engineered and generated using our AMP-Rx platform and are developing as a topical treatment for dry eye disease and allergic conjunctivitis. In 2013, we completed a Phase 1b/2a clinical trial of EBI-005 in patients with moderate to severe dry eye disease. We plan to initiate a pivotal Phase 3 clinical program evaluating EBI-005 for the treatment of moderate to severe dry eye disease in early 2014. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
16 |
Founded: |
2008 |
|
| Contact Information |
| Address: |
215 First Street, Suite 400, Cambridge, MA 02142, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.8 mil (last 12 months) |
|
| Net Income: |
$ -21.7 mil (last 12 months) |
|
| IPO Profile |
|
|
|
|
